Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 13/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305227 | 0.93 | SLC29A1 (0.45) | SLC29A1NT5EPDE2AADORA3ADORA2A | |
| SCHEMBL20347358 | 0.87 | NT5E (0.46) | SLC29A1NT5ELMNA | |
| SCHEMBL20347357 | 0.87 | NT5E (0.45) | NT5E | |
| SCHEMBL19948581 | 0.86 | PDE2A (0.47) | NT5EPDE2AADORA3ADORA2AADORA1 | |
| SCHEMBL30262559 | 0.86 | PDE2A (0.47) | NT5EPDE2AADORA3ADORA2AADORA1 | |
| SCHEMBL19948584 | 0.86 | PDE2A (0.47) | NT5EPDE2AADORA3ADORA2AADORA1 | |
| SCHEMBL20305395 | 0.86 | PDE2A (0.47) | NT5EPDE2AADORA3ADORA2AADORA1 | |
| SCHEMBL20305394 | 0.86 | PDE2A (0.47) | NT5EPDE2AADORA3ADORA2AADORA1 | |
| SCHEMBL20347356 | 0.83 | NT5E (0.50) | NT5E | |
| SCHEMBL20305384 | 0.83 | NT5E (0.46) | SLC29A1NT5ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | SLC29A1 120/4885NT5E 1/4885PDE2A 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.